Progression of a Solitary, Malignant Cutaneous Plasma-Cell Tumour to Multiple Myeloma in a Cat

Total Page:16

File Type:pdf, Size:1020Kb

Progression of a Solitary, Malignant Cutaneous Plasma-Cell Tumour to Multiple Myeloma in a Cat Case Report Progression of a solitary, malignant cutaneous plasma-cell tumour to multiple myeloma in a cat A. Radhakrishnan1, R. E. Risbon1, R. T. Patel1, B. Ruiz2 and C. A. Clifford3 1 Mathew J. Ryan Veterinary Hospital of the University of Pennsylvania, Philadelphia, PA, USA 2 Antech Diagnostics, Farmingdale, NY, USA 3 Red Bank Veterinary Hospital, Red Bank, NJ, USA Abstract An 11-year-old male domestic shorthair cat was examined because of a soft-tissue mass on the left tarsus previously diagnosed as a malignant extramedullary plasmacytoma. Findings of further diagnostic tests carried out to evaluate the patient for multiple myeloma were negative. Five Keywords hyperproteinaemia, months later, the cat developed clinical evidence of multiple myeloma based on positive Bence monoclonal gammopathy, Jones proteinuria, monoclonal gammopathy and circulating atypical plasma cells. This case multiple myeloma, pancytopenia, represents an unusual presentation for this disease and documents progression of an plasmacytoma extramedullary plasmacytoma to multiple myeloma in the cat. Introduction naemia, although it also can occur with IgG or IgA Plasma-cell neoplasms are rare in companion ani- hypersecretion (Matus & Leifer, 1985; Dorfman & mals. They represent less than 1% of all tumours in Dimski, 1992). Clinical signs of hyperviscosity dogs and are even less common in cats (Weber & include coagulopathy, neurologic signs (dementia Tebeau, 1998). Diseases represented in this category and ataxia), dilated retinal vessels, retinal haemor- of neoplasia include multiple myeloma (MM), rhage or detachment, and cardiomyopathy immunoglobulin M (IgM) macroglobulinaemia (Dorfman & Dimski, 1992; Forrester et al., 1992). and solitary plasmacytoma (Vail, 2001). These con- Coagulopathy can result from the M-component ditions can result in an excess secretion of Igs interfering with the normal function of platelets or (paraproteins or M-component) which produce a clotting factors. Renal dysfunction is often asso- monoclonal spike via serum protein electrophoresis. ciated with MM and may be the result of damage MM is a systemic proliferation of neoplastic by Bence Jones proteins, tumour infiltration, Correspondence address: plasma cells from the bone marrow. Consequences hypercalcaemia, amyloidosis or decreased perfu- Dr Anant Radhakrishnan of the systemic disease include bone pathology sion (MacEwen & Hurvitz, 1977). Other clinical Mathew J. Ryan Veterinary (lysis), hyperviscosity syndrome, blood dyscra- manifestations of MM include polyuria or poly- Hospital of the University sias, cytopenias and organ failure (MacEwen & dipsia secondary to hypercalcaemia or renal fail- of Pennsylvania 3900 Delancey Street Hurvitz, 1977). M-component elevation may ure, spinal pain and pathologic fractures. A Philadelphia, lead to hyperviscosity syndrome, characterized by diagnosis of MM requires at least two of four PA 19104-6010, USA increased serum viscosity, blood sludging and criteria: (1) greater than 20% plasma cells in the Tel: þ1 215 898 3207 Fax: þ1 215 573 6050 poor oxygen delivery to tissues. Hyperviscosity bone marrow, (2) monoclonal gammopathy, (3) e-mail: [email protected] occurs more commonly with IgM macroglobuli- osteolytic lesions and (4) Ig light chains (Bence 36 ª 2004 Blackwell Publishing Ltd Feline multiple myeloma and plasmacytoma 37 Jones protein) in the urine (Drazner, 1982; Eastman, revealed four lobulated, soft-tissue masses that 1996; Weber & Tebeau, 1998; Bienzle et al., 2000). encompassed the tarsus circumferentially. Radio- In contrast to MM, plasmacytomas are solitary graphs of the affected extremity revealed no evi- tumours containing neoplastic plasma cells. In dence of osteolysis. Complete blood count (CBC) dogs, two types of plasmacytomas have been and serum chemistry results were unremarkable. described: extramedullary and solitary osseous Segmental resection was carried out to remove forms that originate from soft tissue and bone, two of the lateral masses. Histopathology revealed respectively. Extramedullary plasmacytomas are a poorly differentiated polymorphous blastic-type commonly cutaneous and typically benign, and malignant plasma-cell tumour that stained posi- surgical excision is often curative (Mandel & tively for amyloid. Serum protein electrophoresis, Esplin, 1994). Non-cutaneous extramedullary whole-body radiographs (thorax and abdomen) plasmacytomas tend to be more aggressive and and bone marrow aspiration were carried out to are commonly associated with gastrointestinal further investigate the extent of disease. Serum tract, and typically, there is metastasis to the protein electrophoresis revealed a mild elevation local lymph nodes (Brunnert et al., 1992; Trevor of alpha-2 globulin concentration (1.65 g dLÀ1, et al., 1993; Jackson et al., 1994). Systemic pro- reference interval 0.2–1.5), consistent with an gression to MM is not typical with extramedullary inflammatory process. Radiographs revealed no plasmacytomas (Vail, 2001). Osseous plasmacyto- evidence of osteolytic lesions. Cytologic examin- mas occur in long bones, vertebral bodies, the ation of a bone marrow aspirate was interpreted as zygomatic arch and ribs. In dogs, solitary osseous erythroid hypoplasia, with only rare macrophages plasmacytomas can progress to MM (MacEwen and plasma cells reported. et al., 1984). The patient was transferred to a referral centre 4 There is a paucity of information in the veter- months later for further staging to rule out inary literature regarding plasmacytoma and MM abdominal organ involvement in anticipation of in the cat (Carothers et al., 1989; Forrester et al., radiation therapy. CBC and serum chemistry 1992; Larsen & Carpenter, 1994; Mandel & Esplin, results again were unremarkable. Abdominal 1994; Eastman, 1996; Sheafor et al., 1996; Weber & ultrasonography revealed an enlarged medial iliac Tebeau, 1998; Zikes et al., 1998; Bienzle et al., lymph node. Fine-needle aspiration of the lymph 2000; Hickford et al., 2000). In the cat, MM carries node was consistent with metastatic plasma-cell a poor prognosis, particularly when compared tumour (Fig. 1). Based on the diagnosis of metastasis with plasmacytomas, which may respond to sur- from the original solitary plasmacytoma, the patient gery alone (Mandel & Esplin, 1994). Cats with was referred to the oncology service of the Veterin- MM do not typically develop osseous lesions nor ary Hospital of the University of Pennsylvania, do they commonly develop solitary osseous plas- approximately 6 months after the initial identifica- macytomas (Weber & Tebeau, 1998). Although case tion of the mass and 4 months after the initial reports exist documenting plasmacytoma with a workup for MM. monoclonal gammopathy (Carothers et al., 1989; At presentation, the owner reported no clinical Larsen & Carpenter, 1994; Mandel & Esplin, 1994), abnormalities, with the exception of the soft-tissue to the authors’ knowledge, progression of a solitary mass overlying the tarsus. Physical and ophthalmo- plasmacytoma to MM has not been reported in the scopic examinations were otherwise unremarkable. cat. This report describes a cat with a solitary extra- The cat’s body weight was 8.04 kg. Measurements of medullary plasmacytoma that progressed to MM. the mass were slightly greater than those taken 2 months earlier. A CBC indicated a normal leucocyte count (5.65 K mLÀ1, reference interval 4.0–18.7), Clinical report neutropenia (0.760 K mLÀ1, reference interval An 11-year-old intact male domestic shorthair cat 2.30–14.0), normocytic, normochromic anaemia was examined by the local veterinarian for a mass (hematocrit 27.5%, reference interval 31.7–48.0) around the left tarsus. Physical examination and thrombocytopenia (platelet count 55.1 K mLÀ1, ª 2004 Blackwell Publishing Ltd, Veterinary and Comparative Oncology, 2, 1, 36–42 38 A. Radhakrishnan et al. Figure 1. (A) Cytologic smear made from an ultrasound-guided fine-needle aspirate of an iliac lymph node from a cat. There are large round-to-ovoid neoplastic cells admixed with moderate numbers of small lymphocytes and abundant blood [Wright– Giemsa stain, bar ¼ 40 mm]. (B) Two neoplastic round cells with a slight paranuclear Golgi clearing. One is binucleated, whereas the second cell shows a cleaved nucleus [Wright–Giemsa stain, bar ¼ 5 mm] reference interval 175–500). Cytologic review of the spike was detected within gamma globulin fraction blood smear revealed 53% (2.99 K mLÀ1)ofthe (3.73 g dLÀ1, reference interval 0.5–1.90) on serum leucocytes to be atypical plasma cells (Fig. 2). protein electrophoresis. Ig quantification by radial Abnormalities on serum chemistry included hyper- immunodiffusion identified an IgA gammopathy proteinaemia (11.7 g dLÀ1, reference interval 6.0–8.6), (IgA concentration >2000 mg dLÀ1, reference inter- hyperglobulinaemia (8.4 g dLÀ1, reference interval val 102–582). Radiographs of the thorax and abdo- 2.2–6.2), hypernatraemia (162 mmol LÀ1, reference men revealed no evidence of osteolytic lesions. The interval 146–157) and elevated aspartate aminotrans- bone marrow aspirate was haemodiluted precluding ferase activity (59 U LÀ1, reference interval 1–37). definitive analysis, but 73% of the nucleated cells Bence Jones proteins were detected in the urine with (500 cell differential count) were atypical plasma classical heat precipitation methods. A monoclonal cells. Based upon the monoclonal gammopathy, Bence Jones proteinuria and atypical plasma cells in blood, a diagnosis of MM was made. There was no evidence of
Recommended publications
  • Extraosseous Plasmacytoma with an Aggressive Course Occurring Solely in the CNS
    bs_bs_banner Neuropathology 2013; 33, 320–323 doi:10.1111/j.1440-1789.2012.01352.x Case Report Extraosseous plasmacytoma with an aggressive course occurring solely in the CNS William Wu, Whitney Pasch, Xiaohui Zhao and Sherif A. Rezk Department of Pathology & Laboratory Medicine, University of California, Irvine (UCI), Irvine, California, USA Extraosseous (extramedullary) plasmacytoma is a rela- defined as the presence of monoclonal plasma cells in the tively indolent neoplasm that constitutes 3–5% of all CSF during the course of plasma cell myeloma.3 In addition, plasma cell neoplasms. Rare cases have been reported to few cases of extraosseous plasmacytomas involving the truly occur in the CNS and not as an extension from a nasal nasal septum or sinuses have been reported to extend into lesion. EBV expression in plasma cell neoplasms has been the CNS.4 Given that involvement of the CNS as the initial reported in very few cases that are mainly post-transplant and sole presentation of plasma cell neoplasms is exceed- or occurring in severely immunosuppressed patients. ingly rare and their association with EBV has not previously We report a case of extraosseous plasmacytoma with been well-documented,we present an unusual case of extra- an aggressive course in an HIV-positive individual that osseous plasmacytoma expressing EBV and presenting in occurred solely in the CNS, showing EBV expression by in the CNS of a 40-year-old HIV-positive man. situ hybridization, and presenting as an intraparenchymal mass as well as in the CSF. CASE REPORT Key words: aggressive, central nervous system (CNS), A 40-year-old HIV-positive Hispanic man was admitted to Epstein–Barr virus (EBV), human immunodeficiency virus the Emergency Room for altered mental status, fever, (HIV), plasmacytoma.
    [Show full text]
  • 1 Activity of the Second Generation BTK Inhibitor Acalabrutinib In
    Activity of the Second Generation BTK Inhibitor Acalabrutinib in Canine and Human B-cell Non-Hodgkin Lymphoma Dissertation Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Bonnie Kate Harrington Graduate Program in Comparative and Veterinary Medicine The Ohio State University 2018 Dissertation Committee John C. Byrd, M.D., Advisor Amy J. Johnson, Ph.D. Krista La Perle, D.V.M., Ph.D. William C. Kisseberth, D.V.M., Ph.D. 1 Copyrighted by Bonnie Kate Harrington 2018 2 Abstract Acalabrutinib (ACP-196) is a second-generation inhibitor of Bruton’s Tyrosine Kinase (BTK) with increased target selectivity and potency compared to ibrutinib. In these studies, we evaluated acalabrutinib in spontaneously occurring canine lymphoma, a model of B-cell malignancy reported to be similar to human diffuse large B-cell lymphoma (DLBCL), as well as primary human chronic lymphocytic leukemia (CLL) cells. We demonstrated that acalabrutinib potently inhibited BTK activity and downstream B-cell receptor (BCR) effectors in CLBL1, a canine B-cell lymphoma cell line, primary canine lymphoma cells, and primary CLL cells. Compared to ibrutinib, acalabrutinib is a more specific inhibitor and lacked off-target effects on the T-cell and NK cell kinase IL-2 inducible T-cell kinase (ITK) and epidermal growth factor receptor (EGFR). Accordingly, acalabrutinib did not antagonize antibody dependent cell cytotoxicity mediated by NK cells. Finally, acalabrutinib inhibited proliferation and viability in CLBL1 cells and primary CLL cells and abrogated chemotactic migration in primary CLL cells. To support our in vitro findings, we conducted a clinical trial using companion dogs with spontaneously occurring B-cell lymphoma.
    [Show full text]
  • Up-Date on Solitary Plasmacytoma and Its Main Differences with Multiple Myeloma P
    Experimental Oncology 27, 7-12, 2005 (March) 7 Exp Oncol 2005 27, 1, 7-12 UP-DATE ON SOLITARY PLASMACYTOMA AND ITS MAIN DIFFERENCES WITH MULTIPLE MYELOMA P. Di Micco1,*, B. Di Micco2 1Thrombosis center, Instituto Clinico Humanitas, Milan, Italy 2Clinical Chemistry, University of Sannio, Benevento, Italy Solitary plasmacytoma is plasma cell neoplasm. It is a localized bone disease and for this reason it is different from multiple myeloma (systemic plasma cell neoplasm). Sometimes, solitary plasmacytoma precedes a following multi- ple myeloma. Clinical findings of solitary plasmacytoma are related to the univocal localization on damaged bone, while laboratory findings could be similar to multiple myeloma (i.e. M component, kidney dysfunction, blood calcium alterations, increased β-2-microglobulin). However, during a solitary plasmacytoma, laboratory findings could not be present contemporaneously such clinical complications (i.e. kidney failure, immunological disorders with a trend toward infectious disease and/or autoimmunity, neurological disorders, haematological disorders, amyloidosis, POEMS syndrome). These raise the reason because solitary plasmacytoma has better prognosis compared to multiple myeloma. Key Words: solitary plasmacytoma, multiple myeloma. General information damages are principally related to light chains and are Plasmacytoma, a clonal neoplastic disorder of bone quickly eliminated representing the Beence-Jones pro- marrow that originates from plasma cells, the last mat- tein in the urine [9, 10]. Moreover, immunoglobulin pro- uration stage of B lymphocytes [1-2], may appear as duced by plasmacytoma may be insoluble if cold tem- three different diseases: multiple myeloma (systemic perature is present, so causing a cryoglobulinemia [5, disease), extramedullary plasmacytoma and solitary 11], in particular if a chronic C viral hepatitis is associ- plasmacytoma (localized bone disease) [3].
    [Show full text]
  • Spotlight on Ixazomib: Potential in the Treatment of Multiple Myeloma Barbara Muz Washington University School of Medicine in St
    Washington University School of Medicine Digital Commons@Becker Open Access Publications 2016 Spotlight on ixazomib: Potential in the treatment of multiple myeloma Barbara Muz Washington University School of Medicine in St. Louis Rachel N. Ghazarian Washington University School of Medicine in St. Louis Monica Ou Washington University School of Medicine in St. Louis Micha J. Luderer Washington University School of Medicine in St. Louis Hubert D. Kusdono Washington University School of Medicine in St. Louis See next page for additional authors Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs Recommended Citation Muz, Barbara; Ghazarian, Rachel N.; Ou, Monica; Luderer, Micha J.; Kusdono, Hubert D.; and Azab, Abdel K., ,"Spotlight on ixazomib: Potential in the treatment of multiple myeloma." Drug Design, Development and Therapy.2016,10. 217-226. (2016). https://digitalcommons.wustl.edu/open_access_pubs/5207 This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact [email protected]. Authors Barbara Muz, Rachel N. Ghazarian, Monica Ou, Micha J. Luderer, Hubert D. Kusdono, and Abdel K. Azab This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/open_access_pubs/5207 Journal name: Drug Design, Development and Therapy Article Designation: Review Year: 2016 Volume:
    [Show full text]
  • Evidence-Based Practice Center Systematic Review Protocol
    Evidence-based Practice Center Systematic Review Protocol Project Title: Serum-Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias I. Background and Objectives for the Systematic Review Plasma cell dyscrasias (PCDs) are a spectrum of disorders characterized by the expansion of a population of monoclonal bone-marrow plasma cells that produce monoclonal immunoglobulins.1 At the benign end of the spectrum is monoclonal gammopathy of undetermined significance (MGUS), where the plasma-cell clone usually does not expand. Multiple myeloma (MM) is a plasma cell disorder at the malignant end of the spectrum and is characterized by the neoplastic proliferation of a clone of plasma cells in the bone marrow with resulting end-organ damage, including skeletal destruction (lytic bone lesions), hypercalcemia, anemia, and renal insufficiency. Whereas monoclonal plasma cells generally secrete intact immunoglobulin, in about 20 percent of patients with MM these cells only produce light-chain monoclonal proteins (i.e., light-chain multiple myeloma [LCMM], formerly known as Bence Jones myeloma) and in 3 percent of patients they secrete neither light- nor heavy-chain monoclonal proteins that are detectable by immunofixation (i.e., nonsecretory multiple myeloma [NSMM]).1 In two-thirds of patients with NSMM, a monoclonal protein can be identified by the serum-free light chain (SFLC) assay. Patients with LCMM develop complications related to tissue deposition of light chains, including amyloidosis. Amyloid light-chain (AL) amyloidosis is the most common form of systemic amyloidosis seen in the United States and is characterized by a relatively stable, slow-growing plasma-cell clone that secretes light-chain proteins that form Table 1: Diagnostic criteria and clinical course of selected plasma cell dyscrasias (PCDs)2 Disorder Disease Definition Clinical Course Monoclonal gammopathy of .
    [Show full text]
  • Noninfectious Mixed Cryoglobulinaemic Glomerulonephritis and Monoclonal Gammopathy of Undetermined Significance: a Coincidental Association? Adam L
    Flavell et al. BMC Nephrology (2020) 21:293 https://doi.org/10.1186/s12882-020-01941-3 CASE REPORT Open Access Noninfectious mixed cryoglobulinaemic glomerulonephritis and monoclonal gammopathy of undetermined significance: a coincidental association? Adam L. Flavell1* , Robert O. Fullinfaw2, Edward R. Smith1,3, Stephen G. Holt1,3, Moira J. Finlay3,4 and Thomas D. Barbour1,3 Abstract Background: Cryoglobulins are cold-precipitable immunoglobulins that may cause systemic vasculitis including cryoglobulinaemic glomerulonephritis (CGN). Type 1 cryoglobulins consist of isolated monoclonal immunoglobulin (mIg), whereas mixed cryoglobulins are typically immune complexes comprising either monoclonal (type 2) or polyclonal (type 3) Ig with rheumatoid activity against polyclonal IgG. Only CGN related to type 1 cryoglobulins has been clearly associated with monoclonal gammopathy of undetermined significance (MGUS) using the conventional serum-, urine- or tissue-based methods of paraprotein detection. Case presentation: We present four patients with noninfectious mixed (type 2 or 3) CGN and MGUS. Two patients had type 2 cryoglobulinaemia, one had type 3 cryoglobulinaemia, and one lacked definitive typing of the serum cryoprecipitate. The serum monoclonal band was IgM-κ in all four cases. Treatments included corticosteroids, cyclophosphamide, plasma exchange, and rituximab. At median 3.5 years’ follow-up, no patient had developed a haematological malignancy or advanced chronic kidney disease. Other potential causes of mixed cryoglobulinaemia were also present in our cohort, notably primary Sjögren’s syndrome in three cases. Conclusion: Our study raises questions regarding the current designation of type 2 CGN as a monoclonal gammopathy of renal significance, and the role of clonally directed therapies for noninfectious mixed CGN outside the setting of haematological malignancy.
    [Show full text]
  • Instant Notes: Immunology, Second Edition
    Immunology Second Edition The INSTANT NOTES series Series Editor: B.D. Hames School of Biochemistry and Molecular Biology, University of Leeds, Leeds, UK Animal Biology 2nd edition Biochemistry 2nd edition Bioinformatics Chemistry for Biologists 2nd edition Developmental Biology Ecology 2nd edition Immunology 2nd edition Genetics 2nd edition Microbiology 2nd edition Molecular Biology 2nd edition Neuroscience Plant Biology Chemistry series Consulting Editor: Howard Stanbury Analytical Chemistry Inorganic Chemistry 2nd edition Medicinal Chemistry Organic Chemistry 2nd edition Physical Chemistry Psychology series Sub-series Editor: Hugh Wagner Dept of Psychology, University of Central Lancashire, Preston, UK Psychology Cognitive Psychology Forthcoming title Physiological Psychology Immunology Second Edition P.M. Lydyard Department of Immunology and Molecular Pathology, Royal Free and University College Medical School, University College London, London, UK A. Whelan Department of Immunology, Trinity College and St James’ Hospital, Dublin, Ireland and M.W. Fanger Department of Microbiology and Immunology, Dartmouth Medical School, Lebanon, New Hampshire, USA © Garland Science/BIOS Scientific Publishers Limited, 2004 First published 2000 This edition published in the Taylor & Francis e-Library, 2005. “To purchase your own copy of this or any of Taylor & Francis or Routledge’s collection of thousands of eBooks please go to www.eBookstore.tandf.co.uk.” Second edition published 2004 All rights reserved. No part of this book may be reproduced or
    [Show full text]
  • POEMS Syndrome and Small Lymphocytic Lymphoma Co-Existing in the Same Patient: a Case Report and Review of the Literature
    Open Access Annals of Hematology & Oncology Special Article - Hematology POEMS Syndrome and Small Lymphocytic Lymphoma Co-Existing in the Same Patient: A Case Report and Review of the Literature Kasi Loknath Kumar A1,2*, Mathur SC3 and Kambhampati S1,2* Abstract 1Department of Hematology and Oncology, Veterans The coexistence of B-cell Chronic Lymphocytic Leukemia/Small Affairs Medical Center, Kansas City, Missouri, USA Lymphocytic Lymphoma (CLL/SLL) and Plasma Cell Dyscrasias (PCD) has 2Department of Internal Medicine, Division of rarely been reported. The patient described herein presented with a clinical Hematology and Oncology, University of Kansas Medical course resembling POEMS syndrome. The histopathological evaluation Center, Kansas City, Kansas, USA of the bone marrow biopsy established the presence of an osteosclerotic 3Department of Pathology and Laboratory Medicine, plasmacytoma despite the absence of monoclonal protein in the peripheral Veterans Affairs Medical Center, Kansas City, Missouri, blood. Cytochemical analysis of the plasmacytoma demonstrated monotypic USA expression of lambda (λ) light chains, a typical finding associated with POEMS *Corresponding authors: Kambhampati S and Kasi syndrome. A subsequent lymph node biopsy performed to rule out Castleman’s Loknath Kumar A, Department of Internal Medicine, disease led to an incidental finding of B-CLL/SLL predominantly involving the Division of Hematology and Oncology, University of B-zone of the lymph node. The B-CLL population expressed CD19, CD20, CD23, Kansas Medical Center, Kansas City, 2330 Shawnee CD5, HLA-DR, and kappa (κ) surface light chains. To the best of our knowledge, Mission Parkway, MS 5003, Suite 210, Westwood, KS, a simultaneous manifestation of CLL/SLL and POEMS has not been previously 66205, Kansas, USA, Tel: 9135886029; Fax: 9135884085; reported in the literature.
    [Show full text]
  • Initial Evaluation of the Patient with Waldenstro¨ M Macroglobulinemia Can Be Challenging
    Initial Evaluation of the Patient with Waldenstro¨m Macroglobulinemia Jorge J. Castillo, MD*, Steven P. Treon, MD, PhD KEYWORDS Waldenstro¨ m macroglobulinemia Bone marrow aspiration Anemia Hyperviscosity Cryoglobulinemia Peripheral neuropathy Bing-Neel syndrome Amyloidosis KEY POINTS The initial evaluation of the patient with Waldenstro¨ m macroglobulinemia can be challenging. Not only is Waldenstro¨ m macroglobulinemia a rare disease, but the clinical features of pa- tients with Waldenstro¨ m macroglobulinemia can vary greatly from patient to patient. The authors provide concise and practical recommendations for the initial evaluation of patients with Waldenstro¨ m macroglobulinemia, specifically regarding history taking, physical examination, laboratory testing, bone marrow aspiration and biopsy evaluation, and imaging studies. The authors review the most common special clinical situations seen in patients with Wal- denstro¨ m macroglobulinemia, especially anemia, hyperviscosity, cryoglobulinemia, pe- ripheral neuropathy, extramedullary disease, Bing-Neel syndrome, and amyloidosis. INTRODUCTION Given its rarity and a highly variable clinical presentation, the initial evaluation of the patient with a clinicopathologic diagnosis of Waldenstro¨ m macroglobulinemia (WM) can be challenging. The clinical manifestations of WM can be associated with infiltra- tion of the bone marrow and other organs by malignant lymphoplasmacytic cells and/ or the properties of the monoclonal IgM paraproteinemia, and include anemia, hyper- viscosity,
    [Show full text]
  • Cryoglobulinemia in Sjögren Syndrome: a Disease Subset That
    The Journal of Rheumatology Cryoglobulinemia in Sjögren Syndrome: A Disease Subset that Links Higher Systemic Disease Activity, Autoimmunity, and Local B Cell Proliferation in Mucosa-associated Lymphoid Tissue Luca Quartuccio, Chiara Baldini, Roberta Priori, Elena Bartoloni, Francesco Carubbi, Alessia Alunno, Saviana Gandolfo, Serena Colafrancesco, Roberto Giacomelli, Roberto Gerli, Guido Valesini, Stefano Bombardieri, Salvatore De Vita and the GRISS Group DOI: 10.3899/jrheum.161465 http://www.jrheum.org/content/early/2017/05/09/jrheum.161465 1. Sign up for TOCs and other alerts http://www.jrheum.org/alerts 2. Information on Subscriptions http://jrheum.com/faq 3. Information on permissions/orders of reprints http://jrheum.com/reprints_permissions The Journal of Rheumatology is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields. Downloaded from www.jrheum.org on July 31, 2017 - Published by The Journal of Rheumatology Cryoglobulinemia in Sjögren Syndrome: A Disease Subset that Links Higher Systemic Disease Activity, Autoimmunity, and Local B Cell Proliferation in Mucosa-associated Lymphoid Tissue Luca Quartuccio, Chiara Baldini, Roberta Priori, Elena Bartoloni, Francesco Carubbi, Alessia Alunno, Saviana Gandolfo, Serena Colafrancesco, Roberto Giacomelli, Roberto Gerli, Guido Valesini, Stefano Bombardieri, and Salvatore De Vita, the GRISS Group ABSTRACT. Objective. To compare systemic disease activity by validated tools, i.e., the European League Against Rheumatism Sjögren Syndrome Disease Activity Index (ESSDAI) and the Clinical ESSDAI (ClinESSDAI) scores, between primary Sjögren syndrome (pSS) with positive serum cryoglobulins and pSS without serum cryoglobulins. Methods. There were 825 consecutive patients with pSS who were retrospectively evaluated.
    [Show full text]
  • Understanding the Cryoglobulinemias
    Current Rheumatology Reports (2019) 21:60 https://doi.org/10.1007/s11926-019-0859-0 VASCULITIS (L ESPINOZA, SECTION EDITOR) Understanding the Cryoglobulinemias Alejandro Fuentes1 & Claudia Mardones1 & Paula I. Burgos1 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Purpose of the Review Cryoglobulins are immunoglobulins with the ability to precipitate at temperatures <37 °C. They are related to hematological disorders, infections [especially hepatitis C virus (HCV)], and autoimmune diseases. In this article, the state of the art on Cryoglobulinemic Vasculitis (CV), in a helpful and schematic way, with a special focus on HCV related Mixed Cryoglobulinemia treatment are reviewed. Recent Findings Direct – acting antivirals (DAA) against HCV have emerged as an important key in HCV treatment to related Cryoglobulinemic Vasculitis, and should be kept in mind as the initial treatment in non–severe manifestations. On the other hand, a recent consensus panel has published their recommendations for treatment in severe and life threatening manifestations of Mixed Cryoglobulinemias. Summary HCV-Cryoglobulinemic vasculitis is the most frequent form of CV. There are new treatment options in HCV-CV with DAA, with an important number of patients achieving complete response and sustained virologic response (SVR). In cases of severe forms of CV, treatment with Rituximab and PLEX are options. The lack of data on maintenance therapy could impulse future studies in this setting. Keywords HCV . Mixed Cryoglobulinemia . Type I Cryoglobulinemia . gC1qR . Direct-acting antivirals . Rituximab Introduction and Definitions tion of the total pool of cryoprecipitable immunocomplexes in targeted vessels and due to false negative results owing to im- Cryoglobulins are immunoglobulins (Ig) that precipitate in vitro proper blood sampling or inadequate laboratory processes [4].
    [Show full text]
  • Cardiac Nonamyloidotic Immunoglobulin Deposition Disease
    Modern Pathology (2006) 19, 233–237 & 2006 USCAP, Inc All rights reserved 0893-3952/06 $30.00 www.modernpathology.org Cardiac nonamyloidotic immunoglobulin deposition disease Amir A Toor1,6, Ben A Ramdane1, Jacob Joseph2, Maria Thomas3, Carl O’Hara4, Bart Barlogie1, Patrick Walker5 and Lija Joseph3,4,7 1Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA; 2Division of Cardiovascular Medicine, Boston University School of Medicine, Boston, MA, USA; 3Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, USA; 4Department of Pathology, Mallory Institute of Pathology, Boston Medical Center, Boston University School of Medicine, Boston, MA, USA and 5Nephropathology Associates, Little Rock, AR, USA Cardiac nonamyloidotic immunoglobulin (Ig) deposition disease (CIDD) is a rare disorder characterized by Ig deposition in the myocardium associated with plasma cell dyscrasias. A retrospective review of cardiac biopsies performed at two different institutions identified eight patients with CIDD. All patients had plasma cell dyscrasias with monoclonal gammopathy. Three had IgG k, two had IgG j, one had IgD j and one each had free j and free k light chain. Four patients had concurrent amyloidosis involving other organs. One had amyloidosis of kidney alone, one had amyloidosis of kidney and abdominal fat pad and two others had amyloidosis of bone marrow vasculature. Three patients had dialysis-dependent renal insufficiency. None of the patients had symptoms of heart failure. Six patients had echocardiographically demonstrable concentric left ventricular hypertrophy with diastolic dysfunction. Two patients had significant cardiac arrhythmias requiring medical intervention. On endomyocardial biopsy, all eight had normal appearing myocardium on light microscopy with negative Congo Red and Thioflavin T stains.
    [Show full text]